| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/25/2001 | WO2001036436A1 Gallotannins and ellagitannins as regulators of cytokine release |
| 05/25/2001 | WO2001036432A2 18 human secreted proteins |
| 05/25/2001 | WO2001036431A1 Diamino platinum (ii) antitumor complexes |
| 05/25/2001 | WO2001036425A2 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 05/25/2001 | WO2001036423A1 Spiro(2h-1-benzopyran-2,4'-piperidine) derivates as glycine transport inhibitors |
| 05/25/2001 | WO2001036422A1 Tricyclic dihydropyrimidine potassium channel openers |
| 05/25/2001 | WO2001036421A1 Novel [1,2,3]-triazolo[4,5-d]pyrimidine compounds |
| 05/25/2001 | WO2001036419A1 Use of 9-substituted hypoxanthine derivatives to stimulate regeneration of nervous tissue |
| 05/25/2001 | WO2001036417A1 New use and novel n-azabicyclo-amide derivatives |
| 05/25/2001 | WO2001036416A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | WO2001036415A1 Pesticidal aminoheterocyclamide compounds |
| 05/25/2001 | WO2001036413A1 Aryloxy propanolamines for improving livestock production |
| 05/25/2001 | WO2001036412A1 Process for the preparation of aryloxy propanolamines |
| 05/25/2001 | WO2001036411A1 Crystalline salts of (s)-4-(3-[n-(2-[4-(5-carbamoyl-2-pyridyloxy)phenyl]-1,1-dimethylethyl)amino]-2-hydroxypropoxy)indole |
| 05/25/2001 | WO2001036409A1 Magnesium omeprazole |
| 05/25/2001 | WO2001036408A1 Compounds with antibacterial and antiparasitic properties |
| 05/25/2001 | WO2001036407A1 Novel amidine derivatives, preparation and use thereof as medicines |
| 05/25/2001 | WO2001036404A1 Compounds and methods |
| 05/25/2001 | WO2001036403A1 Urea derivatives as anti-inflammatory agents |
| 05/25/2001 | WO2001036402A1 Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| 05/25/2001 | WO2001036401A1 Solid state forms of 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-2,4-thiazolidinedione |
| 05/25/2001 | WO2001036398A1 Benzoxa- and benzthiazoles |
| 05/25/2001 | WO2001036396A1 Use of benzotriazole uv absorbers |
| 05/25/2001 | WO2001036395A1 Triazoles as farnesyl transferase inhibitors |
| 05/25/2001 | WO2001036394A1 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer |
| 05/25/2001 | WO2001036391A1 Thiamin disulfide derivatives |
| 05/25/2001 | WO2001036390A1 Indazolyloxy propanolamines for improving livestock production |
| 05/25/2001 | WO2001036388A1 Aza compounds having neuronal activity |
| 05/25/2001 | WO2001036384A1 Polymorphic form of atorvastatin calcium |
| 05/25/2001 | WO2001036375A1 Aminoalcohol derivatives useful for the treatment of gastrointestinal disorders |
| 05/25/2001 | WO2001036374A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments |
| 05/25/2001 | WO2001036365A2 Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders |
| 05/25/2001 | WO2001036360A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 05/25/2001 | WO2001036048A1 Phorboxazole derivatives for treating cancer |
| 05/25/2001 | WO2001036007A2 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | WO2001035999A1 Stable amorphous amifostine composition, and preparation thereof |
| 05/25/2001 | WO2001035983A1 Pharmaceutical composition for treatment of diarrhea |
| 05/25/2001 | WO2001035978A1 Targeted bifunctional molecules and therapies based thereon |
| 05/25/2001 | WO2001035976A1 Treatment or prevention of photoaging and skin cancer |
| 05/25/2001 | WO2001035975A2 Treatment of subnormal bone mineral density |
| 05/25/2001 | WO2001035974A2 Aplidine treatment of cancers |
| 05/25/2001 | WO2001035973A1 Method for reducing postprandial oxidative stress using cocoa procyanidins |
| 05/25/2001 | WO2001035972A1 Therapeutic uses of specially processed garlic for sickle cell disease |
| 05/25/2001 | WO2001035970A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | WO2001035967A1 Heparanase inhibitors for the treatment of heart failure |
| 05/25/2001 | WO2001035966A1 Boron compounds and complexes as anti-inflammatory agents |
| 05/25/2001 | WO2001035965A1 Treatment of rosacea |
| 05/25/2001 | WO2001035964A1 Substituted 1-benzazepines and derivatives thereof |
| 05/25/2001 | WO2001035963A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 05/25/2001 | WO2001035962A1 Solutions containing epinastine |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035960A1 Use of substituted 4-(quinolin 2-yl-methoxy)phenyl-acetic acid derivatives for the treatment of diseases |
| 05/25/2001 | WO2001035959A1 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders |
| 05/25/2001 | WO2001035958A1 Carvedilol methanesulfonate |
| 05/25/2001 | WO2001035957A1 Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 05/25/2001 | WO2001035956A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER |
| 05/25/2001 | WO2001035955A1 Benzene derivatives and use thereof as drugs |
| 05/25/2001 | WO2001035954A1 Method for treating gastrointestinal disorders |
| 05/25/2001 | WO2001035953A2 Exercise and muscle enhancement formulations |
| 05/25/2001 | WO2001035952A2 Radiosensitization of human glioblastoma cells by quinazoline compounds |
| 05/25/2001 | WO2001035951A2 Aryl nitrone therapeutics and methods for treating inflammatory bowel disease |
| 05/25/2001 | WO2001035950A2 Benzamide therapeutics and methods for treating inflammatory bowel disease |
| 05/25/2001 | WO2001035949A2 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/25/2001 | WO2001035948A2 Neurophilin ligands for treating ocular conditions |
| 05/25/2001 | WO2001035947A2 Treating wasting syndromes with aryloxy propanolamines |
| 05/25/2001 | WO2001035946A2 Intranasal administration of raloxifene and tamoxifen |
| 05/25/2001 | WO2001035945A2 Use of prostaglandin a2 for the treatment and prophylaxis of priapism |
| 05/25/2001 | WO2001035944A2 Composition for the prevention and/or treatment of disorders due to abnormal lipid metabolism, comprising propionyl l-carnitine and chitosan |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035942A2 Analgesic compositions containing buprenorphine |
| 05/25/2001 | WO2001035941A2 Novel composition based on a thiazolidinedione and metformin and use |
| 05/25/2001 | WO2001035940A2 Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
| 05/25/2001 | WO2001035939A2 Oleamide in epilepsy |
| 05/25/2001 | WO2001035938A2 Pharmacologically active tetrahydro thiopyran-4-ol derivatives, method for their production and use thereof |
| 05/25/2001 | WO2001035937A2 Lipid complex of alkycyclines |
| 05/25/2001 | WO2001035936A2 Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides for the treatment of diseases |
| 05/25/2001 | WO2001035935A2 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 05/25/2001 | WO2001035933A2 A method of microencapsulation |
| 05/25/2001 | WO2001035927A2 Topical application of muscarinic analgesic drugs such as neostigmine |
| 05/25/2001 | WO2001035926A2 An improved pharmaceutical composition for treating male erectile dysfunction |
| 05/25/2001 | WO2001035920A1 Cosmetic compositions containing chick pea extract and retinoids |
| 05/25/2001 | WO2001035918A1 Mint flavor and aroma compositions |
| 05/25/2001 | WO2001035911A1 Cosmetic composition comprising at least a film-forming polymer and at least a regulating agent |
| 05/25/2001 | WO2001035902A2 Stabilized thyroxine compounds |
| 05/25/2001 | WO2001035899A2 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 05/25/2001 | WO2001035883A1 Transdermal delivery system for alkaloids of aconitum species |
| 05/25/2001 | WO2001035739A1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 05/25/2001 | WO2001013909A3 Compositions and methods for treating opiate intolerance |
| 05/25/2001 | WO2001013905A3 Methods for the treatment of mental and vascular disorders |
| 05/25/2001 | WO2001010446A3 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/25/2001 | WO2001008693A3 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/25/2001 | WO2001007433A3 Quinoline derivatives and their use as antibacterial agents |
| 05/25/2001 | WO2001007432A3 Aminopiperidine derivatives as antibacterials |
| 05/25/2001 | WO2001007023A3 Azetidine compounds in cns and eye diseases |
| 05/25/2001 | WO2001005384A3 Manumycin derivatives for treating parasitic disorders |
| 05/25/2001 | WO2001004349A3 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 05/25/2001 | WO2001003678A3 Transdermal therapeutic system for the utilization of tolterodine |
| 05/25/2001 | WO2001000223A3 Multiple agent diabetes therapy |
| 05/25/2001 | WO2000078320A8 Cartilage enhancing food supplements and methods of preparing the same |
| 05/25/2001 | WO2000078290A3 Pharmaceutical composition comprising a salt of paroxetine |